pet-imaging
(4)
RadioMedix and the cancer drugs that race the clock
A radioactive medicine has two jobs: find its target and arrive before its useful activity fades. RadioMedix has spent two decades working on both, from PET imaging to an investigational alpha therapy licensed to Sanofi.
Albert Luderer
He spent thirty years turning lab science into products doctors actually use. Now he is betting that a synthetic peptide can beat the antibody at its own game.
Indi Molecular
Indi Molecular is a Culver City, California biotech developing a synthetic alternative to antibodies called Protein Catalyzed Capture (PCC) agents - small, stable cyclic peptides built with click chemistry that bind protein targets with antibody-like specificity while behaving like small-molecule drugs. Spun out of Caltech chemist James Heath's lab in 2013, the company applies its platform to targeted oncology therapeutics and PET imaging agents, aiming to reach targets long considered undruggable, including KRAS G12D pancreatic cancer and ovarian cancer.
Enhao Gong
Enhao Gong is the CEO and co-founder of Subtle Medical, a Stanford-born AI healthcare company that has earned 9 FDA clearances for deep learning-powered medical imaging products. A PhD graduate from Stanford in Electrical Engineering, Gong co-founded Subtle Medical in 2017 alongside Stanford neuroradiologist Dr. Greg Zaharchuk, and has grown the company to serve 1,000+ scanner installations globally, touching 2.5 million patients annually. Before Subtle Medical, he co-founded Polarr, an AI photo-editing startup used by tens of millions. He has been recognized by Forbes 30 Under 30 (China/APAC, 2018), Fortune 40 Under 40, and Radiology Business 40 Under 40 (2024), and led Subtle Medical to TIME's World's Top HealthTech Companies list in 2025.